Get Started

ABBV

AbbVie (ABBV)

AbbVie Inc

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:ABBV

<< Previous 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Next >>

Date	Time	Source	Headline	Symbol	Company
10/20/2022	9:46AM	Dow Jones News	AbbVie Buying DJS Antibodies for $255 Million	NYSE:ABBV	AbbVie Inc
10/20/2022	9:24AM	PR Newswire (Canada)	AbbVie obtient l'approbation de Santé Canada pour l'emploi de SKYRIZI® (risankizumab), premier et seul inhibiteur spécifique de l'interleukine 23 destiné au traitement de la maladie de Crohn modérément à fortement évolutive chez les adultes	NYSE:ABBV	AbbVie Inc
10/20/2022	9:01AM	PR Newswire (Canada)	AbbVie's SKYRIZI® (risankizumab) Receives Health Canada Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults	NYSE:ABBV	AbbVie Inc
10/20/2022	9:00AM	PR Newswire (US)	AbbVie Acquires DJS Antibodies, Further Strengthening Immunology Pipeline	NYSE:ABBV	AbbVie Inc
10/17/2022	9:09AM	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:ABBV	AbbVie Inc
10/17/2022	9:00AM	PR Newswire (US)	AbbVie Vice Chairman of External Affairs and Chief Legal Officer Laura J. Schumacher to Retire	NYSE:ABBV	AbbVie Inc
10/13/2022	7:01AM	PR Newswire (Canada)	À l'occasion de la Journée mondiale de la vue, une nouvelle application est accessible au Canada aux personnes atteintes de glaucome, le voleur silencieux de la vue	NYSE:ABBV	AbbVie Inc
10/13/2022	7:01AM	PR Newswire (Canada)	For World Sight Day, new app available for Canadians living with glaucoma, the Silent Thief of Sight	NYSE:ABBV	AbbVie Inc
10/07/2022	2:07PM	TipRanks	AbbVie’s Allergan to present eight scientific abstracts at ASDS meeting	NYSE:ABBV	AbbVie Inc
10/07/2022	2:05PM	PR Newswire (US)	Allergan Aesthetics to Present Data from Its Leading Aesthetic Portfolio at the 2022 American Society for Dermatologic Surgery Meeting	NYSE:ABBV	AbbVie Inc
10/04/2022	8:00AM	PR Newswire (US)	AbbVie to Host Third-Quarter 2022 Earnings Conference Call	NYSE:ABBV	AbbVie Inc
09/29/2022	7:00AM	PR Newswire (US)	AbbVie Highlights Robust Gastroenterology Portfolio with New Data in Crohn's Disease and Ulcerative Colitis at the UEG Week 2022	NYSE:ABBV	AbbVie Inc
09/27/2022	7:01AM	PR Newswire (Canada)	XEN® 63 Gel Implant available now for patients with primary open angle glaucoma where previous medical treatments have failed	NYSE:ABBV	AbbVie Inc
09/27/2022	7:01AM	PR Newswire (Canada)	L'implant de gel XEN® 63 est maintenant offert aux patients atteints de glaucome primaire à angle ouvert lorsque les traitements médicaux antérieurs ont échoué	NYSE:ABBV	AbbVie Inc
09/22/2022	8:00AM	PR Newswire (US)	The Forces of Beauty® Report from The DREAM Initiative® Reveals Demand for New Standards of Beauty and Imagery	NYSE:ABBV	AbbVie Inc
09/19/2022	2:00AM	PR Newswire (US)	AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderate to Severe Crohn's Disease	NYSE:ABBV	AbbVie Inc
09/15/2022	2:00AM	PR Newswire (US)	AbbVie to Present Data from Growing Neuroscience and Movement Disorders Portfolio at 2022 MDS International Congress	NYSE:ABBV	AbbVie Inc
09/14/2022	11:15AM	PR Newswire (US)	AbbVie Announces Public Voting Open for 30th Annual Cystic Fibrosis Scholarship "Thriving Student Awards"	NYSE:ABBV	AbbVie Inc
09/13/2022	8:45AM	PR Newswire (US)	Allergan Aesthetics and BOTOX® Cosmetic (OnabotulinumtoxinA) Reveal New 'See Yourself' Campaign Cast, Spotlighting 25 Real People and Their Stories	NYSE:ABBV	AbbVie Inc
09/10/2022	3:20AM	PR Newswire (US)	New Late-Breaking Results from Phase 3 Trials of SKYRIZI® (risankizumab) Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100	NYSE:ABBV	AbbVie Inc
09/09/2022	10:26AM	PR Newswire (US)	AbbVie Declares Quarterly Dividend	NYSE:ABBV	AbbVie Inc
09/08/2022	8:18AM	TipRanks	Exxon (XOM), AbbVie (ABBV): Befriend These 2 Dividend Aristocrat Stocks	NYSE:ABBV	AbbVie Inc
09/08/2022	4:30AM	PR Newswire (US)	New MEASURE-AD Analyses Evaluate Clinical, Psychosocial and Economic Burdens in Atopic Dermatitis Patients	NYSE:ABBV	AbbVie Inc
09/08/2022	4:00AM	PR Newswire (US)	AbbVie to Present Data From its Robust Migraine Portfolio at the Migraine Trust International Symposium 2022	NYSE:ABBV	AbbVie Inc
09/07/2022	8:45AM	PR Newswire (US)	Allergan Aesthetics Celebrates 100 Million Syringes of JUVÉDERM®	NYSE:ABBV	AbbVie Inc
09/07/2022	8:00AM	PR Newswire (US)	AbbVie to Present at the Morgan Stanley Healthcare Conference	NYSE:ABBV	AbbVie Inc
09/01/2022	10:26AM	TipRanks	3 Dividend Kings Analyst are Rating as a Strong Buy	NYSE:ABBV	AbbVie Inc
08/31/2022	9:00AM	PR Newswire (US)	SkinMedica® Launches Firm & Tone Lotion for Body	NYSE:ABBV	AbbVie Inc
08/30/2022	8:00AM	PR Newswire (US)	Allergan Aesthetics publishes 'The Future of Aesthetics' global trends report	NYSE:ABBV	AbbVie Inc
08/29/2022	8:00AM	PR Newswire (US)	AbbVie Showcases New Analyses and Real-World Data Across Multiple Immune-Mediated Skin Diseases at the European Academy of Dermatology and Venereology (EADV) 2022 Congress	NYSE:ABBV	AbbVie Inc